Alanosine in Treating Patients With Cancer

Completed · Phase 2

Conditions studied: Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.

Key facts

Study ID

NCT00062283

Run by

Memorial Sloan Kettering Cancer Center

Starts

2003-03-01

Expected to finish

2009-12-01

Last updated by the study team

2013-06-26

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson, Arizona, United States
• Wilshire Oncology Medical Group, Incorporated - La Verne — La Verne, California, United States
• Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center — Los Angeles, California, United States
• Lynn Regional Cancer Center West — Boca Raton, Florida, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Midwest Cancer Research Group, Incorporated — Skokie, Illinois, United States
• St. Vincent's Comprehensive Cancer Center - Manhattan — New York, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center at University of Texas — Houston, Texas, United States
• U.S. Oncology, Incorporated — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.